Effects of the etonogestrel-releasing implant Implanon and a nonmedicated intrauterine device on the growth of breast-fed infants.
The study objectives were to compare the effects of an etonogestrel-releasing implant (Implanon) and a nonmedicated intrauterine device (IUD) on parameters of lactation in breast-feeding women and on the growth of their breast-fed infants over a 3-year period. Healthy lactating women (28-56 days postpartum) chose either the implant (n=42) or the IUD (n=38). Infant growth during a 3-year follow-up period is reported here. Total duration of breast-feeding coinciding with the mothers' treatment was 421.0 and 423.4 days in the Implanon and IUD groups, respectively. There were no differences between the infant groups in terms of body length, biparietal head circumference and body weight. No abnormalities were reported in psychomotor development or during physical examination. No treatment-related side effects were observed in either group. In conclusion, there were no differences in the growth of breast-fed infants of women treated with Implanon or a nonmedicated IUD. Implanon, therefore, appears to be a safe contraceptive option for breast-feeding women and their infants.
Taneepanichskul
Surasak
S
Department of Obstetrics and Gynaecology, Chulalongkorn Hospital, 10330 Bangkok, Thailand.
Reinprayoon
Damrong
D
Thaithumyanon
Pimolratn
P
Praisuwanna
Pramote
P
Tosukhowong
Piyaratana
P
Dieben
Thom
T
D001942:Breast Feeding; D002657:Child Development / Q000187:drug effects*; D003271:Contraceptive Agents, Female / Q000008:administration & dosage / Q000009:adverse effects*; D017135:Desogestrel / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007223:Infant; D007434:Intrauterine Devices; D008297:Male
D003271:Contraceptive Agents, Female; C044815:etonogestrel; D017135:Desogestrel